Literature DB >> 32324487

Cancer Treatment Adaptations in the COVID-19 Era.

Federico Waisberg1, Diego Enrico1, Martín Angel1, Matías Chacón1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32324487      PMCID： PMC7292479          DOI： 10.1200/OP.20.00218

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  16 in total

1.  Treatment duration of checkpoint inhibitors for NSCLC.

Authors:  Jordi Remon; Jessica Menis; Sandrine Aspeslagh; Benjamin Besse
Journal:  Lancet Respir Med       Date:  2019-08-07       Impact factor: 30.700

2.  Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.

Authors:  Allison Betof Warner; Jessica S Palmer; Alexander N Shoushtari; Debra A Goldman; Katherine S Panageas; Sara A Hayes; Raazi Bajwa; Parisa Momtaz; Margaret K Callahan; Jedd D Wolchok; Michael A Postow; Paul B Chapman
Journal:  J Clin Oncol       Date:  2020-02-13       Impact factor: 44.544

3.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Authors:  Christophe Tournigand; Andres Cervantes; Arie Figer; Gérard Lledo; Michel Flesch; Marc Buyse; Laurent Mineur; Elisabeth Carola; Pierre-Luc Etienne; Fernando Rivera; Isabel Chirivella; Nathalie Perez-Staub; Christophe Louvet; Thierry André; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

4.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Authors:  Axel Grothey; Alberto F Sobrero; Anthony F Shields; Takayuki Yoshino; James Paul; Julien Taieb; John Souglakos; Qian Shi; Rachel Kerr; Roberto Labianca; Jeffrey A Meyerhardt; Dewi Vernerey; Takeharu Yamanaka; Ioannis Boukovinas; Jeffrey P Meyers; Lindsay A Renfro; Donna Niedzwiecki; Toshiaki Watanabe; Valter Torri; Mark Saunders; Daniel J Sargent; Thierry Andre; Timothy Iveson
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

5.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Authors:  Sandro Pignata; Giovanni Scambia; Dionyssios Katsaros; Ciro Gallo; Eric Pujade-Lauraine; Sabino De Placido; Alessandra Bologna; Beatrice Weber; Francesco Raspagliesi; Pierluigi Benedetti Panici; Gennaro Cormio; Roberto Sorio; Maria Giovanna Cavazzini; Gabriella Ferrandina; Enrico Breda; Viviana Murgia; Cosimo Sacco; Saverio Cinieri; Vanda Salutari; Caterina Ricci; Carmela Pisano; Stefano Greggi; Rossella Lauria; Domenica Lorusso; Claudia Marchetti; Luigi Selvaggi; Simona Signoriello; Maria Carmela Piccirillo; Massimo Di Maio; Francesco Perrone
Journal:  Lancet Oncol       Date:  2014-02-28       Impact factor: 41.316

6.  Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.

Authors:  Debora de Melo Gagliato; Ana M Gonzalez-Angulo; Xiudong Lei; Richard L Theriault; Sharon H Giordano; Vicente Valero; Gabriel N Hortobagyi; Mariana Chavez-Macgregor
Journal:  J Clin Oncol       Date:  2014-01-27       Impact factor: 44.544

7.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

Authors:  Penella J Woll; Peter Reichardt; Axel Le Cesne; Sylvie Bonvalot; Alberto Azzarelli; Harald J Hoekstra; Michael Leahy; Frits Van Coevorden; Jaap Verweij; Pancras C W Hogendoorn; Monia Ouali; Sandrine Marreaud; Vivien H C Bramwell; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

8.  Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Authors:  Joseph A Sparano; Fengmin Zhao; Silvana Martino; Jennifer A Ligibel; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

9.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Authors:  Helena M Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Adrian N Harnett; Mei-Lin Ah-See; Richard Simcock; Daniel Rea; Sanjay Raj; Pamela Woodings; Mark Harries; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Janine Mansi; Ioannis Gounaris; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Jean E Abraham; Carlos Caldas; Peter S Hall; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn
Journal:  Lancet       Date:  2019-06-06       Impact factor: 79.321

10.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Authors:  Wenhua Liang; Weijie Guan; Ruchong Chen; Wei Wang; Jianfu Li; Ke Xu; Caichen Li; Qing Ai; Weixiang Lu; Hengrui Liang; Shiyue Li; Jianxing He
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316
View more
  8 in total

1.  Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!

Authors:  Satya Ranjan Misra; Rupsa Das
Journal:  Oral Oncol       Date:  2022-03-28       Impact factor: 5.972

2.  COVID-19: Thoracic Diagnostic Interventional Procedures in Troubled Times.

Authors:  Luis Gorospe; Ana María Ayala-Carbonero; Almudena Ureña-Vacas; Montserrat Medina-Díaz; Paola Arrieta; Rosa Mariela Mirambeaux-Villalona; Deisy Barrios-Barreto; Gemma María Muñoz-Molina; Alberto Cabañero-Sánchez; Yolanda Lage-Alfranca; Margarita Martín-Martín; Amparo Benito-Berlinches; Javier Alarcón-Rodríguez
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-05-31       Impact factor: 4.872

Review 3.  Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?

Authors:  Mikhail Kiselevskiy; Irina Shubina; Irina Chikileva; Suria Sitdikova; Igor Samoylenko; Natalia Anisimova; Kirill Kirgizov; Amina Suleimanova; Tatyana Gorbunova; Svetlana Varfolomeeva
Journal:  Pharmaceuticals (Basel)       Date:  2020-07-26

4.  Chemotherapy in the Covid-19 era: the patient's perception.

Authors:  Maeve A Hennessy; Anna Linehan; Darren Cowzer; Zachary L Coyne; Orla Fitzpatrick; Fiona Barrett; Roisin Ni Dhonaill; Bryan T Hennessy; Liam Grogan; Patrick G Morris; Oscar S Breathnach
Journal:  Ir J Med Sci       Date:  2021-01-15       Impact factor: 1.568

5.  First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.

Authors:  Agustín Falco; Mariano Leiva; Albano Blanco; Guido Cefarelli; Andrés Rodriguez; Juan Melo; Federico Cayol; Manglio Miguel Rizzo; Alejandro Sola; Hernán Rodríguez Montani; Matías Chacon; Diego Enrico; Federico Waisberg
Journal:  World J Clin Oncol       Date:  2022-02-24

6.  Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study.

Authors:  Natalia Valdiviezo; Cindy Alcarraz; Denisse Castro; Renzo Salas; Victor Begazo-Mollo; Marco Galvez-Villanueva; Luz Medina Aguirre; Elica Garcia-León; Isela Quispe-Santivañez; Carmen Cornejo-Raymundo; Eduardo Paz-Cornejo; Luis Sanchez-Vilela; Vanessa Bermudez-Alfaro; Juan Carlos Vargas-Nina; Carlos Pérez-Ramos; Andrea Meza-Hoces; Paolo R Valdez Barreto; Ruth Huaringa-Leiva; Johanny Muro-Cieza; Valeria Aguilar-Vásquez; Eduardo Yache Cuenca; Silvia Neciosup-Delgado; Nathaly Poma-Nieto; Sheyla Chavez-Gavino; Lenin Fernandez-Rosas; Jhajaira M Araujo; Eduardo Payet; Henry L Gomez
Journal:  Cancer Manag Res       Date:  2022-03-08       Impact factor: 3.989

7.  Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris.

Authors:  Camille Tlemsani; Jennifer Arrondeau; Sixtine De Percin; Ithar Gataa; Marie Bretagne; Zahra Ajgal; Olivier Huillard; Marie Wislez; Romain Coriat; Jerome Alexandre; Pascaline Boudou-Rouquette; François Goldwasser
Journal:  Clin Med (Lond)       Date:  2021-08-02       Impact factor: 5.410

8.  Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic.

Authors:  Debra Wujcik; William N Dudley; Matthew Dudley; Vibha Gupta; Jeannine Brant
Journal:  Value Health       Date:  2022-03-23       Impact factor: 5.101
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.